Simpson Thacher represented KKR in the transaction.
KKR executed its acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Ltd. (NSE: JBCHEPHARM) (“J.B. Chemicals”) through acquisition of shares from the founding Mody family at a purchase price of INR 745 per share and an open offer for an additional 26% stake. The transaction is subject to regulatory and other customary approvals.
J.B. Chemicals is listed on the BSE and NSE, and is one of the leading pharmaceutical companies in India, supplying affordable, high-quality products in the cardiac, gastrointestinal and anti-infective therapeutic areas across the branded formulations market, which are exported to more than 40 countries around the world. J.B. Chemicals’ contract manufacturing capabilities also allow it to partner with large, international brands to develop a diverse range of innovative specialty products, including tablets, injectables, creams and ointments, lozenges, herbal liquids and capsules.
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies.
The Simpson Thacher team representing KKR included Ian Ho (Picture), Sonya Ho, Nelson Tai and Mai Kristofferson (M&A); Vanessa Burrows (Healthcare); and Steven DeLott (Insurance).
Involved fees earner: Vanessa Burrows – Simpson Thacher & Bartlett; Steven DeLott – Simpson Thacher & Bartlett; Ian Ho – Simpson Thacher & Bartlett; Sonya Ho – Simpson Thacher & Bartlett; Mai Kristofferson – Simpson Thacher & Bartlett; Nelson Tai – Simpson Thacher & Bartlett;
Law Firms: Simpson Thacher & Bartlett;